Kantarjian H, Thomas D, O’Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101:2788–801.

Article  CAS  PubMed  Google Scholar 

Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106:3760–7.

Article  CAS  PubMed  Google Scholar 

Huguet F, Chevret S, Leguay T, Thomas X, Boissel N, Escoffre-Barbe M, et al. Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial. J Clin Oncol. 2018;36:2514–23.

Article  CAS  PubMed  Google Scholar 

Gokbuget N. Treatment of older patients with acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2016;2016:573–9.

Article  Google Scholar 

Rousselot P, Coude MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128:774–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391:320–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nierengarten MB. Blinatumomab approved as consolidation therapy for MRD-negative B-cell precursor acute lymphoblastic leukemia. Cancer. 2024;130:3622.

CAS  PubMed  Google Scholar 

Romero D. Blinatumomab improves outcomes in adult MRD-negative BCP-ALL. Nat Rev Clin Oncol. 2024;21:703.

CAS  PubMed  Google Scholar 

Stelljes M, Raffel S, Alakel N, Wasch R, Kondakci M, Scholl S, et al. Inotuzumab ozogamicin as induction therapy for patients older than 55 years with philadelphia chromosome-negative B-precursor ALL. J Clin Oncol. 2024;42:273–82.

Article  CAS  PubMed  Google Scholar 

Shouse G, Danilov AV, Artz A. CAR T-cell therapy in the older person: indications and risks. Curr Oncol Rep. 2022;24:1189–99.

Article  CAS  PubMed  Google Scholar 

Connor MP, Frey NV. CAR T in adult ALL: when and for whom?. Best Pr Res Clin Haematol. 2021;34:101256.

Article  CAS  Google Scholar 

DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P, et al. Hematopoietic cell transplantation in the treatment of adult acute lymphoblastic leukemia: updated 2019 evidence-based review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transpl. 2019;25:2113–23.

Article  Google Scholar 

Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2019;54:798–809.

Article  Google Scholar 

Roth-Guepin G, Canaani J, Ruggeri A, Labopin M, Finke J, Cornelissen JJ, et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT. Oncotarget. 2017;8:112972–9.

Article  PubMed  PubMed Central  Google Scholar 

Bazarbachi A, Labopin M, Aljurf M, Niittyvuopio R, Balsat M, Blaise D, et al. 20-year steady increase in survival of adult patients with relapsed philadelphia-positive acute lymphoblastic leukemia post allogeneic hematopoietic cell transplantation. Clin Cancer Res. 2022;28:1004–12.

Article  PubMed  Google Scholar 

Abou Dalle I, Moukalled N, El Cheikh J, Mohty M, Bazarbachi A. Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions. Leukemia. 2024;38:1876–84.

Article  PubMed  Google Scholar 

Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628–33.

Article  Google Scholar 

Bolanos-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bazarbachi A, Labopin M, Moukalled N, Kroger N, Rautenberg C, Schetelig J, et al. Improvements in posttransplant outcomes over two decades in older patients with acute myeloid leukemia in the EBMT ALWP study. Clin Cancer Res. 2024;30:1778–87.

Article  PubMed  Google Scholar 

Shahzad M, Hussain A, Tariq E, Anwar I, Faisal MS, Syed L, et al. Outcomes of tyrosine kinase inhibitors maintenance therapy with or without allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia in first complete remission: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2023;23:178–87.

Article  CAS  PubMed  Google Scholar 

Saini N, Marin D, Ledesma C, Delgado R, Rondon G, Popat UR, et al. Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood. 2020;136:1786–9.

Article  PubMed  PubMed Central  Google Scholar 

Giebel S, Czyz A, Ottmann O, Baron F, Brissot E, Ciceri F, et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2016;122:2941–51.

Article  CAS  PubMed  Google Scholar 

Warraich Z, Tenneti P, Thai T, Hubben A, Amin H, McBride A, et al. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review. Biol Blood Marrow Transpl. 2020;26:e55–e64.

Article  CAS  Google Scholar 

Kim HT, Zhang MJ, Woolfrey AE, St Martin A, Chen J, Saber W, et al. Donor and recipient sex in allogeneic stem cell transplantation: what really matters. Haematologica. 2016;101:1260–6.

Article  PubMed  PubMed Central  Google Scholar 

Ali N, Ullah H, Shaikh MU, Adil SN. Outcome of donor and recipient sex match versus mismatch in stem cell transplant procedure. Int J Hematol Oncol. 2019;8:IJH21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sijs-Szabo A, Dinmohamed AG, Versluis J, van der Holt B, Bellido M, Hazenberg MD, et al. Allogeneic stem cell transplantation in patients >40 years of age with acute lymphoblastic leukemia: reduced intensity versus myeloablative conditioning. Transplantation. 2023;107:2561–7.

CAS  PubMed  Google Scholar 

Mohty M, Labopin M, Volin L, Gratwohl A, Socie G, Esteve J, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116:4439–43.

Article  CAS  PubMed  Google Scholar 

Peric Z, Labopin M, Peczynski C, Polge E, Cornelissen J, Carpenter B, et al. Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT. Bone Marrow Transpl. 2020;55:1560–9.

Article  CAS  Google Scholar 

Khimani F, Dutta M, Faramand R, Nishihori T, Perez AP, Dean E, et al. Impact of total body irradiation-based myeloablative conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: systematic review and meta-analysis. Transpl Cell Ther. 2021;27:620.e1–e9.

Article  Google Scholar 

Hirschbuhl K, Labopin M, Polge E, Blaise D, Bourhis JH, Socie G, et al. Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transpl. 2023;58:874–80.

Article  Google Scholar 

Giebel S, Labopin M, Socie G, Aljurf M, Salmenniemi U, Labussiere-Wallet H, et al. Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transpl. 2023;58:506–13.

Article  CAS  Google Scholar 

Battipaglia G, Labopin M, Mielke S, Ruggeri A, Nur Ozkurt Z, Bourhis JH, et al. Thiotepa-based regimens are valid alternatives to total body irradiation-based reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia: a retrospective study on behalf of the acute leukemia Working Party of the European Society for Blood and Marrow Transplantation. Transpl Cell Ther. 2024;30:95.e1–e10.